GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
9 May 2012 | By GlaxoSmithKline
GSK will not participate in Human Genome Sciences strategic alternatives...
List view / Grid view
News
US and EU regulatory authorities accept oral BG-12 marketing applications for review
9 May 2012 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications for review...
FDA Arthritis Advisory Committee recommends approval of Tofacitinib
9 May 2012 | By Pfizer
“We are pleased with the Committee’s positive evaluation..."
Customers celebrate the launch of Tecan Australia
8 May 2012 | By kdm communications limited
Tecan recently invited customers from around Australasia to mark the inauguration of Tecan Australia as a fully owned Tecan subsidiary...
New data presented at the 2012 Annual Meeting of the APA
8 May 2012 | By H. Lundbeck A/S
Lu AA21004 may have positive effect on cognitive dysfunction in patients with major depressive disorders...
Gilead Sciences to present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16
8 May 2012 | By Gilead Sciences
Webcast available through Gilead Corporate website...
Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
Pfizer announces new long-term relapse prevention data for PRISTIQ® (desvenlafaxine) 50 mg/day
7 May 2012 | By Pfizer
Pfizer announced new data presented at the 165th Annual Meeting of the APA...
Roche provides update on Phase III study of dalcetrapib
7 May 2012 | By Roche
Roche announced that following the results of the second interim analysis of the dalcetrapib dal-OUTCOMES Phase III trial...
Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly
7 May 2012 | By Novartis
Results of the largest Phase III study...
Pfizer stops Phase 3 trial Of Lyrica (pregabalin) capsules CV in neuropathic pain associated with HIV neuropathy
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
James Shannon named GlaxoSmithKline Chief Medical Officer
4 May 2012 | By GlaxoSmithKline
James Shannon has been named GSK’s Chief Medical Officer, effective 1 May...
Pfizer reports top-line results from Phase 3 trial of Lyrica (pregabalin) capsules CV in patients with inadequately treated painful diabetic peripheral neuropathy
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
Alan Schafer to head Population Genetics
3 May 2012 | By Alto Marketing
Population Genetics Technologies Ltd., has appointed Alan Schafer, PhD to the post of Chief Executive Officer...
Gerresheimer shows syringe systems at Korea Pack 2012
3 May 2012 | By Gerresheimer
Gerresheimer will be displaying its comprehensive range of prefillable syringe systems at Booth K701 of the Korea Pack...
